Supplementary Material for: Beyond Biopsy: Real-World Evaluation of the FIB-6 Score in a P

A clinical dataset of 301 adult patients from a Portuguese cohort with steatotic liver disease. The data was used to evaluate the diagnostic performance of the novel Fibrosis-6 (FIB-6) score against established noninvasive scores like FIB-4 and APRI. The study, authored by figshare admin karger and last updated in 2026, analyzed patient demographics, clinical data, and laboratory results against liver stiffness measurements from transient elastography.

Use Cases

• Validate the FIB-6 biomarker for liver fibrosis prediction based on age, AST, ALT, ALP, platelet count, and albumin.
• Compare diagnostic performance of noninvasive scores (FIB-6, FIB-4, APRI) using ROC analysis and correlation with liver stiffness.
• Establish etiology-specific rule-in and rule-out thresholds for advanced fibrosis and cirrhosis in clinical triage.
• Analyze the correlation between composite biomarker scores and liver stiffness measurements across different liver disease etiologies.

Strengths

• Includes data from 301 adult patients who underwent transient elastography, providing a real-world cohort.
• Reports specific performance metrics: FIB-6 AUC for cirrhosis (F4) was 0.716 and for advanced fibrosis (F3-F4) was 0.709.
• Provides concrete cut-off values: optimal Youden cutoffs for FIB-6 were >2.06 for advanced fibrosis and >1.69 for cirrhosis.

Limitations

• Row count is unknown, which may limit suitability assessment for large-scale modeling.
• Column-level documentation is absent; field semantics must be inferred after download.
• Data may reflect geographic bias inherent to the single Portuguese cohort.

Provenance

Source

figshare admin karger

Collection Method

Observational study with retrospective collection of demographic, clinical, and laboratory data from patients who underwent transient elastography.

Freshness

Last updated 2026-04-24 05:55:10; freshness should be verified.

Geography

Portugal